10-Q: LENZ Therapeutics Reports Q3 2025 Results, VIZZ Launch

LENZ Therapeutics, Inc. announced its third-quarter 2025 financial results, highlighting the FDA approval and commercial launch of VIZZ for presbyopia, alongside increased operating expenses for market expansion.

Summary

• The U.S. Food and Drug Administration (FDA) approved VIZZ (aceclidine ophthalmic solution) 1.44% on July 31, 2025, as the first and only aceclidine-based eye drop for the treatment of presbyopia in adults.
• Commercial launch of VIZZ in the U.S. was initiated in August 2025, with professional product sample distribution and commercial product shipments to customers via an e-pharmacy partner starting in October 2025.
• The company anticipates VIZZ will be broadly available in retail pharmacies by the middle of the fourth quarter of 2025.
• Total revenue for the three months ended September 30, 2025, was $12.5 million, compared to $0 for the same period in 2024, primarily from new licensing agreements and regulatory milestones.
• Total revenue for the nine months ended September 30, 2025, was $17.5 million, compared to $0 for the same period in 2024.
• Net loss for the three months ended September 30, 2025, was $(16.7) million, an increase from $(10.2) million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $(46.2) million, compared to $(37.1) million for the same period in 2024.
• The accumulated deficit as of September 30, 2025, reached $191.2 million.
• Cash, cash equivalents, and marketable securities totaled $202.2 million as of September 30, 2025.
• Selling, general and administrative (SG&A) expenses significantly increased to $27.6 million for Q3 2025 (from $6.5 million in Q3 2024) and $51.5 million for the nine months ended September 30, 2025 (from $19.5 million in 2024), driven by commercialization efforts.
• Research and development (R&D) expenses decreased to $3.8 million for Q3 2025 (from $6.5 million in Q3 2024) and $18.7 million for the nine months ended September 30, 2025 (from $23.9 million in 2024), due to the completion of CLARITY trials and reclassification of certain costs.
• The company sold 920,500 shares of common stock for net proceeds of $26.1 million under an at-the-market (ATM) offering during the nine months ended September 30, 2025.
• In October 2025, an additional 2,698,134 shares of common stock were sold at a weighted-average price of $45.79 under the Sales Agreement, utilizing the remaining capacity.

Sentiment

Score: 7

Explanation: The company achieved a major positive milestone with FDA approval and commercial launch of VIZZ, securing NCE exclusivity and significant upfront payments from licensing deals. The strong cash balance provides a runway to achieve positive operating cash flow. However, increased operating losses due to commercialization ramp-up and intense market competition, coupled with historical challenges faced by similar products, introduce notable execution risks. The overall sentiment is positive due to the significant progress, but tempered by the financial burn and competitive landscape.

Positives

• FDA approval of VIZZ (aceclidine ophthalmic solution) 1.44% on July 31, 2025, as the first and only aceclidine-based eye drop for the treatment of presbyopia in adults.
• Successful commercial launch of VIZZ in the U.S. in August 2025, with product distribution and sampling initiated in October 2025.
• Secured five years of New Chemical Entity (NCE) exclusivity for VIZZ in the United States, expiring July 2030.
• Established new international licensing agreements: Lotus License ($5.0 million upfront) for Southeast Asia and Tha License ($2.5 million upfront) for Canada.
• Achieved two regulatory milestones under the CORXEL License, generating $10.0 million in license revenue.
• Maintained a strong cash position with $202.2 million in cash, cash equivalents, and marketable securities as of September 30, 2025.
• Management believes existing cash, cash equivalents, and marketable securities will be sufficient to fund the company to positive operating cash flow.
• Positive topline data from the Phase 3 JX07001 clinical trial of LNZ100 in China was announced in October 2024, meeting primary and key secondary endpoints.

Negatives

• Continued to incur significant net losses, with $(16.7) million in Q3 2025 and $(46.2) million for the nine months ended September 30, 2025.
• Accumulated deficit reached $191.2 million as of September 30, 2025.
• Selling, general and administrative expenses increased substantially by 325% in Q3 2025 and 165% for the nine months ended September 30, 2025, due to commercialization ramp-up.
• Reliance on third-party manufacturers for VIZZ production, with some raw materials sourced from a single-source supplier, introduces supply chain risks.
• Market acceptance of VIZZ is unproven, and prior presbyopia treatments (e.g., Vuity) faced challenges with refill rates due to perceived limited efficacy or duration.
• Faces significant competition in the presbyopia market from major pharmaceutical companies and generic versions of existing products.

Risks

• Limited operating history and anticipated continued losses in the early stages of commercialization.
• Business depends entirely on the development and commercialization of VIZZ, with no additional product candidates in the current development pipeline.
• VIZZ may fail to achieve market acceptance by Eye Care Professionals (ECPs) and patients, or the market opportunity may be smaller than estimated.
• Significant competition from existing branded, generic, and off-label products could negatively impact commercial opportunities.
• Inability to establish or maintain effective sales and marketing capabilities or enter into acceptable third-party agreements.
• Inability to obtain and maintain sufficient intellectual property protection for VIZZ, or if the scope is not broad enough, competitors could develop and commercialize similar products.
• Reliance on third parties for manufacturing increases the risk of insufficient quantities or unacceptable costs, potentially delaying or impairing commercialization efforts.
• Manufacturing difficulties by third-party manufacturers could delay or prevent adequate supply of VIZZ.
• Reliance on third parties (clinical investigators, CROs) to conduct clinical trials; failure to perform could delay or prevent regulatory approval or commercialization.
• Success is highly dependent on the ability to attract and retain highly skilled executive officers and employees.
• The market price of common stock is expected to be volatile.
• Potential for product liability lawsuits, leading to substantial liabilities or limitations on VIZZ commercialization.
• Risks associated with marketing products internationally, including differing regulatory requirements, economic instability, trade policies, and intellectual property enforcement challenges.
• VIZZ's active pharmaceutical ingredient (aceclidine) was previously marketed outside the U.S. for glaucoma, which could lead to adverse side effects if misused or competition from generic forms.
• Inability to protect the confidentiality of trade secrets could harm the business and competitive position.
• Potential claims that employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of former employers or other third parties.
• Trademarks and trade names may not be adequately protected, impeding brand recognition.
• Intellectual property rights may not address all potential threats to competitive advantage.
• Future collaboration or partnership arrangements may not be successful.
• Failure to comply with obligations under any license, collaboration, or other agreements could lead to termination and loss of intellectual property rights.
• The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable.
• Despite FDA approval of VIZZ, the company will be subject to ongoing regulatory obligations and continued regulatory oversight, with potential penalties for non-compliance.
• Disruptions at the FDA, SEC, and other government agencies caused by funding shortages or global health concerns could hinder their ability to perform normal business functions.
• Changes to current regulations and future healthcare legislation (e.g., Inflation Reduction Act, state drug pricing laws) could adversely affect the business and results of operations.
• Subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, and health information privacy and security laws.
• Internal computer systems, or those of third-party contractors, may fail or suffer actual or suspected security or privacy breaches.
• An active trading market for common stock may never develop or be sustained.
• A sale of a substantial number of shares of common stock may cause the price of common stock to decline.
• The board of directors is authorized to issue and designate shares of convertible preferred stock in additional series without stockholder approval, potentially diluting common stockholders.
• Continued status as an emerging growth company and a smaller reporting company may make common stock less attractive to investors.
• Failure to maintain proper and effective internal controls could impair the ability to produce accurate financial statements on a timely basis.
• Corporate governance provisions under Delaware law and the company's certificate of incorporation and bylaws could make an acquisition more difficult.
• Claims for indemnification by directors and officers may reduce available funds.
• Subject to SEC requirements applicable to reporting shell company business combinations, leading to more stringent reporting requirements and offering limitations.
• If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about the company, its stock price and trading volume could decline.
• May be subject to adverse legislative or regulatory tax changes that could negatively impact financial condition (e.g., One Big Beautiful Bill Act).
• Ability to use net operating loss carryforwards and other tax attributes may be limited due to ownership changes (e.g., Section 382 of the Code).
• Unfavorable global economic conditions could adversely affect the business, financial condition, results of operations, or cash flows.

Future Outlook

The company expects to incur additional losses as it hires personnel, protects intellectual property, and grows through the commercialization of VIZZ. Management believes existing cash, cash equivalents, and marketable securities as of September 30, 2025, will be sufficient to fund operations to positive operating cash flow. Selling, general and administrative expenses are projected to continue increasing in 2025 and for the foreseeable future due to commercialization efforts, while research and development costs are expected to decrease over the remainder of 2025 following the completion of CLARITY trials and reclassification of certain expenses. VIZZ is anticipated to be broadly available in retail pharmacies by mid-Q4 2025. The company may require additional financing depending on market acceptance, sales performance, manufacturing costs, regulatory outcomes, and intellectual property enforcement.

Management Comments

• "We believe that a once-daily pharmacological eye drop that can effectively and safely improve near vision throughout the full workday, without the need for reading glasses, is a highly attractive commercial product with an estimated U.S. market opportunity in excess of $3 billion."
• "It is our goal to successfully commercialize VIZZ, and we have assembled an executive team with extensive clinical and commercial experience to execute this goal and become the category leader."
• "We believe that our existing cash, cash equivalents, and marketable securities as of September 30, 2025 will allow us to continue to commercialize VIZZ, and will be sufficient to fund the Company to positive operating cash flow."

Industry Context

VIZZ is positioned as the first and only FDA-approved aceclidine-based eye drop for presbyopia, a condition affecting an estimated 1.8 billion people globally and 128 million in the United States, with an estimated U.S. market opportunity exceeding $3 billion. The presbyopia market has seen prior pharmacologic options like AbbVie's Vuity, which experienced strong initial sales but faced challenges with refill rates due to perceived limited efficacy and duration. Orasis's Qlosi and a generic version of Vuity by Amneal Pharmaceuticals have also entered the market, intensifying competition. VIZZ aims to differentiate itself with a predominantly pupil-selective miotic mechanism, offering up to 10 hours of clear near vision without causing a myopic shift, which the company believes offers advantages over existing treatments.

Comparison to Industry Standards

• VIZZ is the first and only FDA-approved aceclidine-based eye drop for presbyopia, differentiating it from pilocarpine-based competitors like Vuity (AbbVie) and Qlosi (Orasis).
• VIZZ is highlighted for its differentiated mechanism as a predominantly pupil-selective miotic, aiming for a sub-2mm pupil to improve near vision without causing a myopic shift, and claims up to 10 hours of clear near vision.
• Vuity, a competitor, despite an initial strong commercial launch with over 120,000 prescriptions in 2022, experienced lagging refill rates, with a survey indicating 66% of optometrists' patients did not see duration past four hours, and ECPs citing low effectiveness and short duration as key discontinuation factors.
• The company believes VIZZ's clinical data offers advantages over Vuity, although the products have not been evaluated head-to-head.
• A generic version of Vuity was launched by Amneal Pharmaceuticals in August 2025, increasing competition in the market for presbyopia treatments.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to or aware of any legal proceedings that are believed to have, individually or in the aggregate, a material adverse effect on the business, financial condition, or results of operations.
• May be subject to legal proceedings and claims arising in the ordinary course of business from time to time.
• Has been subject to litigation and received demands in connection with the Merger, as previously disclosed in public filings.

Related Party Transactions

• Issued 3,343,330 shares to investors who had designated members on the company's board of directors through the March 2024 PIPE Financing.
• A member of the company's board of directors also serves on the board of a vendor providing manufacturing services. Fees incurred with this vendor were $0.7 million for the nine months ended September 30, 2025 (compared to $0.4 million for the nine months ended September 30, 2024), charged to research and development expenses. No amounts were due to this vendor within accounts payable as of September 30, 2025 (compared to $0.1 million as of December 31, 2024).

Stakeholder Impact

• Shareholders: Potential for increased value from VIZZ's commercial success and NCE exclusivity, but also face dilution risk from future capital raises and stock price volatility due to market competition and operational expenses.
• Employees: Significant growth in headcount, particularly in sales and marketing, indicating job creation and expansion, but also intense competition for skilled personnel.
• Customers (ECPs and Patients): Access to a new, FDA-approved treatment for presbyopia (VIZZ) offering potential for improved near vision, but also the need for a prescription and potential concerns regarding efficacy/duration compared to existing or competing treatments.
• Suppliers/Manufacturers: Continued reliance on third-party manufacturers, including single-source suppliers, for VIZZ production, which could impact supply chain stability and costs.
• Creditors: The company's strong cash position and management's belief in reaching positive operating cash flow suggest a reduced immediate credit risk, but ongoing net losses indicate continued cash burn.

Next Steps

• Continue commercializing VIZZ in the United States, including expanding sales and marketing infrastructure.
• Achieve broad availability of VIZZ in retail pharmacies by mid-Q4 2025.
• Establish additional licensing partnerships internationally to provide access to VIZZ globally.
• Monitor and manage increased selling, general and administrative expenses to support commercial operations.
• Evaluate financing opportunities from time to time to fund operations and planned growth, if needed.
• Comply with ongoing regulatory obligations and post-market surveillance for VIZZ.

Key Dates

Recommendation

The FDA approval and commercial launch of VIZZ are significant positive catalysts, establishing the company in a large market with NCE exclusivity. The strong cash balance provides a runway to achieve positive operating cash flow. However, the substantial increase in SG&A expenses for commercialization, coupled with historical challenges faced by competing presbyopia treatments (e.g., Vuity's refill rates), introduces considerable execution risk. While the market opportunity is large, successful penetration and sustained adoption are unproven. Investors should hold to monitor VIZZ's commercial traction, sales growth, and the company's ability to manage expenses and achieve profitability amidst intense competition.

Keywords

Presbyopia, VIZZ, aceclidine, ophthalmic solution, FDA approval, commercial launch, pharmaceutical, biotechnology, eye care, vision, financial results, 10-Q, LENZ Therapeutics, drug development, market opportunity, intellectual property, regulatory, sales, marketing, clinical trials